Retraction

Potential of antiviral peptide-based SARS-CoV-2 inactivators to combat COVID-19

Retraction Details

Citations (8)

8
Total Citations
6
Post-Retraction
(75.0%)
0
Pre-Retraction
1
Same Day
Post-Retraction Citation Analysis
0 Within 30 days
1 Within 1 year
2 After 2+ years
1004 Days since retraction (latest)
Heavy Metals Removal Using Carbon Based Nanocomposites
Unknown Authors
Unknown Journal
Published: Unknown
Design and in Silico evaluation of 3’,4’-Dimethoxy flavonol as promising SARS-CoV-2 main protease (Mpro) inhibitor
Neni Frimayanti, Ihsan Ikhtiarudin, Roni Ardiyansyah et al. (5 authors)
In Silico Pharmacology
Published: May 2025
1004 days after retraction
Exploration of plant alkaloids as potential inhibitors of <i>HIV</i>–CD4 binding: Insight into comprehensive <i>in silico</i> approaches
Imran Zafar, Zain Abbas, Sidra Abbas et al. (7 authors)
Open Chemistry Open Access
Published: Jan 2025
854 days after retraction
6-Octadecenoic and Oleic Acid in Liquid Smoke Rice Husk Showed COVID-19 Inhibitor Properties
Ira Arundina, Neni Frimayanti, Meircurius Dwi Condro Surboyo et al. (5 authors)
Advances in Pharmacological and Pharmaceutical Sciences Open Access
Published: Apr 2024
4 citations
603 days after retraction
Exploring Substituted Tetrazoloquinazoline: Biological Activities, Molecular Docking Analysis, and Anti‐Breast Cancer MCF7/HER2 Effects
Neni Frimayanti, Ihsan Ikhtiarudin, Rahma Dona et al. (5 authors)
Advances in Pharmacological and Pharmaceutical Sciences Open Access
Published: Jan 2024
1 citation
488 days after retraction
Proteins and Peptides-Based Antibacterial and Antiviral Materials
Mandana Lak, Iman Zare, Hamid Rashedi et al. (6 authors)
ACS symposium series
Published: Dec 2023
1 citation
469 days after retraction
Virtual screening of knottin and defensin peptides perceives hits against the SARS CoV-2 RBD domain and hACE2 interaction
Nitesh Mani Tripathi, Anupam Bandyopadhyay
Unknown Journal Open Access
Published: Jan 2023
1 citation
140 days after retraction
Retraction: Potential of antiviral peptide-based SARS-CoV-2 inactivators to combat COVID-19
Unknown Authors
PLoS ONE Open Access
Published: Aug 2022
Same day as retraction